Please wait a minute...
Reviews in Cardiovascular Medicine  2020, Vol. 21 Issue (3): 365-384     DOI: 10.31083/j.rcm.2020.03.118
Review Previous articles | Next articles
Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection
Ramesh K. Goyal1, *(), Jaseela Majeed1, Rajiv Tonk1, Mahaveer Dhobi1, Bhoomika Patel2, Kalicharan Sharma3, Subbu Apparsundaram1
1Delhi Pharmaceutical Sciences and Research University, New Delhi - 110017, Delhi, India
2Institute of Pharmacy, Nirma University, Ahmedabad - 382481, Gujarat, India
3Mankind Research Center, Gurgaon-122050, Haryana, India
Download:  PDF(5159KB)  ( 519 ) Full text   ( 55 )
Export:  BibTeX | EndNote (RIS)      

Angiotensin-converting enzyme 2 (ACE2), the host cell-binding site for SAR-CoV-2, poses two-fold drug development problems. First, the role of ACE2 itself is still a matter of investigation, and no specific drugs are available targeting ACE2. Second, as a consequence of SARS-CoV-2 interaction with ACE2, there is an impairment of the renin-angiotensin system (RAS) involved in the functioning of vital organs like the heart, kidney, brain, and lungs. In developing antiviral drugs for COVID-19, ACE2, RNA-dependent RNA polymerase (RdRp), and the specific enzymes involved in the viral and cellular gene expression have been the primary targets. SARS-CoV-2 being a new virus with unusually high mortality, there has been a need to get medicines in an emergency, and the drug repurposing has been a primary strategy. Considering extensive mortality and morbidity throughout the world, we have made a maiden attempt to discover the drugs interacting with RAS and identify the lead compounds from herbal plants using molecular docking. Both host ACE2 and viral RNA-dependent RNA polymerase (RdRp) and ORF8 appear to be the primary targets for the treatment of COVID-19. While the drug repurposing of currently approved drugs seems to be one strategy for the treatment of COVID-19, purposing phytochemicals may be another essential strategy for discovering lead compounds. Using in silico molecular docking, we have identified a few phytochemicals that may provide insights into designing herbal and synthetic therapeutics to treat COVID-19.

Key words:  COVID-19      ACE2      SARS-CoV-2      antiviral      phytoconstituents      molecular docking     
Submitted:  20 June 2020      Revised:  21 September 2020      Accepted:  23 September 2020      Published:  30 September 2020     
*Corresponding Author(s):  Ramesh K. Goyal     E-mail:

Cite this article: 

Ramesh K. Goyal, Jaseela Majeed, Rajiv Tonk, Mahaveer Dhobi, Bhoomika Patel, Kalicharan Sharma, Subbu Apparsundaram. Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection. Reviews in Cardiovascular Medicine, 2020, 21(3): 365-384.

URL:     OR

Fig. 1.  Overview of SARS-CoV-2 infection and renin-angiotensin system: During the COVID-19 infection, the SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2) receptors present on the cell surface which undergo endocytosis, and the virus enters inside the cell. Upon entering the cell, it synthesizes RNA using the host metabolic processes in which enzyme RNA dependent RNA polymerase (RdRp) is essential. Due to cellular damage caused by the virus, the alveolar macrophages generate various proinflammatory cytokines like interleukin-6 (IL-6), macrophage inflammatory protein 1α (MIP1α), monocyte chemoattractant protein 1 (MCP1), MIP1β, interferon γ-induced protein-10 (IP-10) resulting in alterations in the vascular permeability. There is leakage of cytokines, promoting more inflammation with dysfunctional immune responses and infiltration of inflammatory cells like monocytes, macrophages, and T-cells, ultimately producing cytokine storm. There is an infiltration of neutrophils that undergoes degranulation leading to the generation of neutrophil extracellular traps (NETs). The circulating ACE2 converts angiotensin (Ang) I to angiotensin1-9 and angiotensin II to angiotensin1-7. The ACE converts angiotensin I to angiotensin II and angiotensin1-9 to angiotensin1-7. Angiotensin II binds to angiotensin 1 (AT1) receptors to produce vasoconstriction, proinflammatory, profibrotic, prothrombotic, and arrhythmogenic action. Angiotensin II also acts on AT2 receptors to mediate tissue protection. Angiotensin 1-7 binds to the MAS receptor to produce vasodilatory, antiproliferative, anti-inflammatosry, antifibrotic, and antithrombotic actions.

Fig. 2.  3D docking pose of rutin into the ACE2 receptor catalytic domain (Pdbid: 2ajf) showing binding interaction with key amino acid residues of backbone protein. The backbone amino acid residues highlighted with grey colour. Binding interaction (hydrogen bonding) depicted with red dashed lines.

Fig. 3.  2D Ligplot interaction of rutin against ACE2 receptor catalytic domain (Pdbid-2ajf). The pose was in 2D form and all the interactions were depicted by red solid lines, hydrophobic amino acid residue denoted by green colour, positive charge residue denoted by blue colour, charged negative residue denoted by red colour, polar residue were denoted by sky blue colour.

Table 1.  Docking scores and binding free energies of phytoconstituents interacting with ACE2 and interacting amino acids.
LigandPhytoconstituent ACE2 Docking scorekcal/mol ACE2amino acids interactingwith the ligand Binding free energykcal/mol
Positive control GL-1001 -6.8 Ala348, Trp349, Asp350, Asp382, Arg393 -60.2
Negative control Captopril -3.7 Tyr385, ASN394 -25.5
1 Rutin -11.5 Ala348, Asp350, Arg393Ser44, Ser47, Phe390, Asn394 -78.2
2 Verbascoside -10.2 Ala348, Asp350, Asp382Glu375, His378, Phe390, Asn394, Glu402 -90.4
3 Hesperidin -9.5 Ala348, Asp350Trp69, Tyr385 -70.3
4 Luteolin 7-O-glucoside -9.3 Ala348, Arg393 Glu375, Phe390, Glu402 -65.3
5 Naringin -9.2 Ala348, Arg393 -65.2
6 Epigallocatechin gallate -8.6 Ala348, Asp350, Asp382, Arg393  Phe390 -72.0
7 Apigenin-7-O-glucoside -8.1 Ala348, Arg393 Glu375, Asn394 -59.2
8 Hesperetin -7.3 Ala348, Arg393 Phe390, Asn394 -57.5
9 Quercetin -7.0 Ala348, Arg393   Phe390 -57.5
10 Naringenin -6.4 Ala348 Phe390 -51.1
11 Dioscin -6.4 Asp350 -57.0
12 Kaempferol -6.3 Ala348, Arg393 Phe390, Asn394 -52.6
13 Apigenin -6.2 Ala348 Phe390 -50.6
14 Luteolin -6.0 Ala348, Arg393  Phe390 -65.3
15 Solanine -6.0 Ala348 Glu402 -42.2
16 Solamargine -5.6 Phe390 -47.4
17 Galangin -5.3 Arg393 Phe390, Asn394 -44.8
18 Acalyphin -5.2 Asp350, Arg393 Asn394 -46.5
19 Solasodine -4.8 Phe390 -42
20 Lantadene A -4.5 Ala348, Asp350 -54.8
21 Oleanolic acid -4.4 Ala348 Asn394 -29.1
22 Lantadene C -4.0 Asp350 -52.2
23 Lantadene B -3.6 Tyr369 50.0
24 Ricinine -3.2 Tyr385 -20.7
25 Solasonine -2.6 None -30.1
ACE2 amino acids interacting with GL-1001, a selective ACE2 inhibitor, are given in bold.
Table 2.  Docking scores and binding free energies of phytoconstituents interacting with AT1 or AT2 and interacting amino acids.
Ligand-Phytoconstituent AT1 Docking score kcal/mol Binding free energy against AT1kcal/mol AT1 amino acids interacting with the ligand AT2 Docking score kcal/mol AT2 amino acids interacting with the ligand Binding free energy against AT2kcal/mol
OlmesartanAT1 antagonist -8.9 -84.3 Tyr35, Trp84, Thr88, Arg167 -6.5 Arg182,Lys215, Trp100 -78.3
PD12377AT2 antagonist -4.9 -85.6 Tyr87, Tyr92 -6.7 Trp100, Phe129, Arg182, Lys215, Phe272 -82.9
1 Rutin -12.6 -95.2 Tyr35, Thr88, Arg167 Tyr87, Phe182, Tyr184, Asp263, Gln267 -11.9 Arg182, Lys215, Phe272 Ser208, Asp279 -91.5
2 Verbascoside -12.3 -91.7 Arg167 Tyr184,Trp253, Gln257 Asp263 -11.6 Arg182, Lys215 Tyr108, Thr276, Asp279, Trp283 -94.8
3 Hesperidin -11.6 -90.3 Tyr35 Ser16, Cys18, Ala21, Tyr87 -10.2 Arg182, Lys215 Thr276, Asp279 -91.0
4 Luteolin 7-O-glucoside -10.5 -76.8 Tyr35 Cys180, Tyr292 -9.7 Arg182, Lys215 Thr125 -68.0
5 Naringin -10.7 -84.1 Tyr35, Thr88, Arg167 Pro19, Ala21, Arg23, Tyr87 -10 Lys215 Cys195, Thr276, Asp279 -83.9
6 Epigallocatechin gallate -7.2 -72.8 Arg167 Ala21, Arg23, Tyr87, Tyr92, Asp263 -9.4 Lys215, Phe272  Thr178 -78.2
7 Apigenin-7-O-glucoside -11.1 -74.9 Arg167 Ala21, Tyr87, Asp281 -10.2 Arg182 Tyr51, Thr125 -74.3
8 Hesperetin -8.0 -50.5 Arg167 Tyr87 -7 Lys215, Phe272  Thr178 -57.7
9 Quercetin -8.4 -55.3 Tyr35  Ala21, Tyr87, Tyr92 -7.5 Lys215, Phe272 Thr178 -54.2
10 Naringenin -8.0 -45.5 Arg167  Tyr87 -7.7 Thr125 Arg182 -50
11 Dioscin -10.0 -58.8 Tyr87 -8.2 Thr125 -54.2
12 Kaempferol -7.0 -46.5 Tyr35, Arg167 Tyr87 -7.3 Phe272 Thr125, Ile304 -50.3
13 Apigenin -7.8 -45.3 Arg167 -7.7 Arg182 Thr125 -48.5
14 Luteolin -9.0 -47.4 Arg167 -7.3 Lys215, Phe272  Thr178 -52.8
15 Solanine -8.4 -33.5 None -8.9 Arg182 -50.1
Fig. 4.  3D docking pose of rutin into the AT1 receptor (Pdbid-4zud) showing binding interaction with key amino acid residues of backbone protein. The backbone amino acid residues highlighted with grey colour while rutin highlighted by green colour. Binding interaction (hydrogen bonding) depicted with red dashed lines. Pi-pi stacking interaction was denoted by blue dashed lines.

Fig. 5.  2D Ligplot interaction of rutin docked in to the AT1 receptor catalytic domain (Pdbid-4zud). The pose was in 2D form and all the interactions were depicted by red solid lines, hydrophobic amino acid residue denoted by green colour, positive charge residue denoted by blue colour, charged negative residue denoted by red colour, polar residue were denoted by sky blue colour.

Fig. 6.  3D docking poses of rutin in to the AT2 receptor catalytic domain (Pdbid-4unf) showing binding interaction with key amino acid residues of backbone protein. The backbone amino acid residues highlighted with grey colour while rutin highlighted by brown colour. Binding interaction (hydrogen bonding) depicted with red dashed lines. Pi-pi stacking interaction was denoted by blue dashed lines.

Fig. 7.  2D Ligplot interaction of rutin docked in to the AT2 receptor catalytic domain (Pdbid-4unf). The pose was in 2D form and all the interactions were depicted by red solid lines, hydrophobic amino acid residue denoted by green colour, positive charge residue denoted by blue colour, charged negative residue denoted by red colour, polar residue were denoted by sky blue colour.

Table 3.  Docking scores and binding free energies of phytoconstituents interaction with viral RdRp and ORF8 interacting amino acids.
Ligand Phytoconstituent RdRp Docking score kcal/mol Binding free energy against RdRp kcal/mol RdRp amino acids interacting with the ligand ORF8 Docking score kcal/mol ORF8 amino acids interacting with the ligand Binding free energy against ORF8 kcal/mol
Uridine Triphosphate -6.7 -56.8 Lys551, Arg553, Arg555, Lys621, Asp760 ND   ND ND
Thymidine derivative -6.5 -53.2 Arg553, Cys622 ND ND ND
Remedisvir -6.7 -61.5 Lys551, Arg555 ND ND ND
metabolite Ser549
1 Rutin -9.0 -90.6 Arg555 -10.9 Tyr42, His45, His58, Lys61, His87 -68.9
Ile548, Arg553, Asp623, Asp760
2 Verbascoside -7.4 -132.7 Lys551, Arg555, -9.9 Lys61, Lys90 -72.7
Asp618, Cys622
3 Hesperidin -10.0 -98.1 Arg555 -14.5 Phe43, His45, His58, Lys61, His87, Asn97 -97.5
Lys545, Ile548, Asp845
4 Luteolin 7-O-glucoside -8.5 -102 Ile548, Ser759, Arg836 -13.1 His58, His87, Tyr42 -74.4
5 Naringin -9.6 -90.9 Asp760 -11.2 His58, His87, Lys90 -63.2
Ser549, Tyr619, Asp623,
6 Epigallocatechin gallate -5.2 -103.7 Ile548, Ser814 -11.6 Tyr42, His58 -54.2
7 Apigenin-7-O-glucoside -8.6 -90.7 Arg555, Asp760 -12.6 Tyr42, His58, His87 -74.8
8 Hesperetin -6.1 -61.5 Arg555 -9.7 His87 -51.5
9 Quercetin -7.8 -62.6 Arg555 -10.5 His87 -53.7
10 Naringenin -6.4 -43.6 Ser682 -9.3 His58, His87 -46.9
11 Dioscin -5.9 -100  Tyr619 -4.2 Lys90 -40.1
12 Kaempferol -5.7 -53.7 Arg555 -9.8 His87 -50.1
13 Apigenin -5.5 -52.1 Arg555 -9.0 His87 -52.1
14 Luteolin -6.4 -54.1 Arg555 -10.0 His87 -52.2
15 Solanine -6.1 -102.9 Ser682 -5.5 His87 -51.2
16 Solamargine -10.8 -72.8 Tyr619 -4.7 Trp42 -43.2
17 Galangin -5.6 -52.1 Arg555 -9.8 Tyr42, His58, His87 -51.2
18 Acalyphin -5.6 -46.6 Asp760 -6.6 His87 -37.5
Asp618, Lys621
19 Solasodine -4.2 -58.6 Asn691 -2.0 Leu91 -16.9
20 Oleanolic acid -3.0 -58.2 Ser549, Tyr619 -1.2 Lys90 -69.2
SARS-CoV-2 RdRp amino acids interacting with uridine triphosphate, are given in bold.
Fig. 8.  3D docking pose of hesperidin in to the RdRp receptor catalytic domain (Pdbid-7bv2) showing binding interaction with key amino acid residue of backbone protein. The backbone amino acid residues highlighted with grey colour while hesperidin highlighted by grey colour, Binding interaction (hydrogen bonding) depicted with red dashed lines. Ionic interaction was denoted by green dashed lines.

Fig. 9.  2D Ligplot interaction of hesperidin docked in to the RdRp receptor catalytic domain (Pdbid-7bv2). The pose was in 2D form and all the interactions were depicted by violet solid lines, hydrophobic amino acid residue denoted by green colour, positive charge residue denoted by blue colour, charged negative residue denoted by red colour, polar residue were denoted by sky blue colour.

Fig. 10.  3D docking pose of hesperidin in to the ORF8 receptor catalytic domain (Pdbid-6bb5) showing binding interaction with key amino acid residue of backbone protein. The backbone amino acid residues highlighted with grey colour while hesperidin highlighted by brown colour Binding interaction (hydrogen bonding) depicted with red dashed lines. pi-pi interaction was denoted by blue dashed lines.

Fig. 11.  2D Ligplot interaction of hesperidin docked in to the ORF8 receptor catalytic domain (Pdbid-6bb5). The pose was in 2D form and all the interactions were depicted by violet solid lines, hydrophobic amino acid residue denoted by green colour, positive charge residue denoted by blue colour, charged negative residue denoted by red colour, polar residue were denoted by sky blue colour.

[1] Abdelli, I., Hassani, F., Brikci, B S. and Ghalem, S. (2020) In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria. Journal of Biomolecular Structure and Dynamics 4, 1-14.
[2] Acanfora, D., Ciccone, M. M., Scicchitano, P., Acanfora, C. and Casucci, G. (2020) Neprilysin inhibitor-angiotensin II receptor blocker combination (Sacubitril/Valsartan): Rationale for adoption in SARS-CoV-2 patients. European Heart Journal - Cardiovascular Pharmacotherapy 6, 135-136.
[3] Amin, M. and Abbas, G. (2020) Docking study of chloroquine and hydroxychloroquine interaction with SARS-CoV-2 spike glycoprotein - an in silico insight into the comparative efficacy of repurposing antiviral drugs. Journal of Biomolecular Structure and Dynamics 6, 1-13.
[4] Antinori, S., Cossu, M. V., Ridolfo, A. L., Rech, R., Bonazzetti, C., Pagani, G., Gubertini, G., Coen, M., Magni, C., Castelli, A., Borghi, B., Colombo, R., Giorgi, R., Angeli, E., Mileto, D., Milazzo, L., Vimercati, S., Pellicciotta, M., Corbellino, M., Torre, A., Rusconi, S., Oreni, L., Gismondo, M. R., Giacomelli, A., Meroni, L., Rizzardini, G. and Galli, M. (2020) Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. Pharmacological Research 158, 104899.
[5] Arthur, J. S. C. and Ley, S. C. (2013) Mitogen-activated protein kinases in innate immunity. Nature Reviews. Immunology 13, 679-692.
[6] Ashburn, T. T. and Thor, K. B. (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery 3, 673-683.
[7] Babadaei, M. M. N., Hasan, A., Bloukh, S. H., Edis, Z., Sharifi, M., Kachooei, E. and Falahati, M. (2020) The expression level of angiotensin-converting enzyme 2 determines the severity of COVID-19: Lung and heart tissue as targets. Journal of Biomolecular Structure and Dynamics 7, 1-7.
[8] Badawi, A. and Ryoo, S. G. (2016) Prevalence of comorbidities in the Middle East Respiratory Syndrome Coronavirus (MERS-CoV): a systematic review and meta-analysis. International Journal of Infectious Diseases 49, 129-133.
[9] Beck, B. R., Shin, B., Choi, Y., Park, S. and Kang, K. (2020) Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Computational and Structural Biotechnology Journal 18, 784-790.
[10] Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., Touloumi, G., Lye, D. C., Ohmagari, N., Oh, M. D., Ruiz-Palacios, G. M., Benfield, T., Fätkenheuer, G., Kortepeter, M. G., Atmar, R. L., Creech, C. B., Lundgren, J., Babiker, A. G., Pett, S., Neaton, J. D., Burgess, T. H., Bonnett, T., Green, M., Makowski, M., Osinusi, A., Nayak, S. and Lane, H. C. (2020) Remdesivir for the Treatment of Covid-19 - preliminary report. New England Journal of Medicine 22, NEJMoa2007764.
[11] Benarba, B. and Pandiella, A. (2020) Medicinal plants as sources of active molecules against COVID-19. Frontiers in Pharmacology 11, 1189.
[12] Benetti, E., Tita, R., Spiga, O., Ciolfi, A., Birolo, G., Bruselles, A., Doddato, G., Giliberti, A., Marconi, C., Musacchia, F., Pippucci, T., Torella, A., Trezza, A., Valentino, F., Baldassarri, M., Brusco, A., Asselta, R., Bruttini, M., Furini, S., Seri, M., Nigro, V., Matullo, G., Tartaglia, M., Mari, F., Study, G.-C. M., Renieri, A. and Pinto, A. M. (2020) ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. European Journal of Human Genetics 17, 1-13.
[13] Bilinska, K., Jakubowska, P., Von Bartheld, C. S. and Butowt, R. (2020) Expression of the SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: Identification of cell types and trends with age. ACS Chemical Neuroscience 11, 1555-1562.
[14] Birnbaum, R. A. (2020) Renin-angiotensin-aldosterone system inhibitors in COVID-19. New England Journal of Medicine 382, e92.
[15] Boukhatem, M. N. and Setzer, W. N. (2020) Aromatic herbs, medicinal plant-derived essential oils, and phytochemical extracts as potential therapies for Coronaviruses: Future perspectives. Plants 9, 800.
[16] Bourgonje, A. R., Abdulle, A. E., Timens, W., Hillebrands, J. L., Navis, G. J., Gordijn, S. J., Bolling, M. C., Dijkstra, G., Voors, A. A., Osterhaus, A. D., Van der Voort, P. H., Mulder, D. J. and Van Goor, H. (2020) Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). Journal of Pathology 251, 228-248.
[17] Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., Yang, Y., Shen, C., Li, X., Peng, L., Huang, D., Zhang, J., Zhang, S., Wang, F., Liu, J., Chen, L., Chen, S., Wang, Z., Zhang, Z., Cao, R., Zhong, W., Liu, Y. and Liu, L. (2020) Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering (in press).
[18] Cannata, F., Chiarito, M., Reimers, B., Azzolini, E., Ferrante, G., My, I., Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy, Viggiani, G., Panico, C., Regazzoli, D., Ciccarelli, M., Voza, A., Aghemo, A., Li, H., Wang, Y., Condorelli, G., and Stefanini, G. G. (2020) Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. European Heart Journal - Cardiovascular Pharmacotherapy (in press).
[19] Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., Yuan, Y., Chen, H., Li, H., Huang, H., Tu, S., Gong, F., Liu, Y., Wei, Y., Dong, C., Zhou, F., Gu, X., Xu, J., Liu, Z., Zhang, Y., Li, H., Shang, L., Wang, K., Li, K., Zhou, X., Dong, X., Qu, Z., Lu, S., Hu, X., Ruan, S., Luo, S., Wu, J., Peng, L., Cheng, F., Pan, L., Zou, J., Jia, C., Wang, J., Liu, X., Wang, S., Wu, X., Ge, Q., He, J., Zhan, H., Qiu, F., Guo, L., Huang, C., Jaki, T., Hayden, F. G., Horby, P. W., Zhang, D. and Wang, C. (2020) A trial of lopinavir-ritonavir in adults hospitalized with Severe Covid-19. New England Journal of Medicine 382, 1787-1799.
[20] Capone, C. A., Subramony, A., Sweberg, T., Schneider, J., Shah, S., Rubin, L., Schleien, C., Epstein, S., Johnson, J. C., Kessel, A., Misra, N., Mitchell, E., Palumbo, N., Rajan, S., Rocker, J., Williamson, K. and Davidson, K. W. (2020) Characteristics, cardiac involvement, and outcomes of multisystem inflammatory syndrome of childhood associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection. the Journal of Pediatrics 224, 141-145.
[21] Cavalli, E., Bramanti, A., Ciurleo, R., Tchorbanov, A., Giordano, A., Fagone, P., Belizna, C., Bramanti, P., Shoenfeld, Y. and Nicoletti, F. (2020) Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review). International Journal of Molecular Medicine 46, 903-912.
[22] Chang, R. and Sun, W. (2020) Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges. Drug Discovery Today
[23] Chen, C. C., Chow, M. P., Huang, W. C., Lin, Y. C. and Chang, Y. J. (2004) Flavonoids inhibit tumor necrosis factor-alpha-induced up-regulation of intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells through activator protein-1 and nuclear factor-kappa b: structure-activity relationships. Molecular Pharmacology 66, 683-693.
[24] Chen, L., Li, X., Chen, M., Feng, Y. and Xiong, C. (2020) The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovascular Research 116, 1097-1100.
[25] Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H. and Doerr, H. (2003) Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. The Lancet 361, 2045-2046.
[26] Chandrasekar, V. T., Venkatesalu, B., Patel, H. K., Spadaccini, M., Manteuffel, J. and Ramesh, M. (2020) Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 Infection. Journal of Medical Virology (in press).
[27] Corley, M. J. and Ndhlovu, L. C. (2020) DNA methylation analysis of the COVID-19 host cell receptor, angiotensin I converting enzyme 2 Gene (ACE2) in the respiratory system reveal age and gender differences. Europe PMC (in press).
[28] Cortegiani, A., Ippolito, M., Ingoglia, G., Iozzo, P., Giarratano, A. and Einav, S. (2020) Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. Journal of Critical Care 59, 176-190.
[29] Crisafulli, S., Isgrò, V., La Corte, L., Atzeni, F. and Trifirò, G. (2020) Potential role of anti-interleukin (IL)-6 drugs in the treatment of COVID-19: Rationale, clinical evidence and risks. Biodrugs 34, 415-422.
[30] Crowley, S. D. and Rudemiller, N. P. (2017) Immunologic effects of the renin-angiotensin system. Journal of the American Society of Nephrology 28, 1350-1361.
[31] Dales, N. A., Gould, A. E., Brown, J. A., Calderwood, E. F., Guan, B., Minor, C. A., Gavin, J. M., Hales, P., Kaushik, V. K., Stewart, M., Tummino, P. J., Vickers, C. S., Ocain, T. D. and Patane, M. A. (2002) Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) Inhibitors. Journal of the American Chemical Society 124, 11852-11853.
[32] Danser, A. H. J., Epstein, M. and Batlle, D. (2020) Renin-angiotensin system blockers and the COVID-19 pandemic. Hypertension 75, 1382-1385.
[33] Davoudi-Monfared, E., Rahmani, H., Khalili, H., Hajiabdolbaghi, M., Salehi, M., Abbasian, L., Kazemzadeh, H. and Yekaninejad, M. S. (2020) A randomized clinical trial of the efficacy and safety of interferon beta-1a in treatment of severe COVID-19. Antimicrobial Agents and Chemotherapy 64, 1-14.
[34] de Maat, S., de Mast, Q., Danser, A. H. J., van de Veerdonk, F. L. and Maas, C. (2020) Impaired breakdown of bradykinin and its metabolites as a possible cause for pulmonary edema in COVID-19 infection. Seminars in Thrombosis and Hemostasis
[35] de Simone, G. and Mancusi, C. (2020) COVID-19: Timing is important. European Journal of Internal Medicine 77, 134-135.
[36] Dehelean, C. A., Lazureanu, V., Coricovac, D., Mioc, M., Oancea, R., Marcovici, I., Pinzaru, I., Soica, C., Tsatsakis, A. M. and Cretu, O. (2020) SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and toxicological screening. Journal of Clinical Medicine 9, 2084.
[37] Del Valle, D. M., Kim-Schulze, S., Hsin-Hui, H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T., Madduri, D., Stock, A., Marron, T., Xie, H., Patel, M. K., van Oekelen, O., Rahman, A., Kovatch, P., Aberg, J., Schadt, E., Jagannath, S., Mazumdar, M., Charney, A., Firpo-Betancourt, A., Mendu, D. R., Jhang, J., Reich, D., Sigel, K., Cordon-Cardo, C., Feldmann, M., Parekh, S., Merad, M. and Gnjatic, S. (2020) An inflammatory cytokine signature helps predict COVID-19 severity and death. medRxiv (in press).
[38] Ding, X., Zhu, F., Yang, Y. and Li, M. (2013) Purification, antitumor activity in vitro of steroidal glycoalkaloids from black nightshade (Solanum nigrum L.). Food Chemistry 141, 1181-1186.
[39] Dyall, J., Coleman, C. M., Hart, B. J., Venkataraman, T., Holbrook, M. R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Jahrling, P. B., Laidlaw, M., Johansen, L. M., Lear-Rooney, C. M., Glass, P. J., Hensley, L. E. and Frieman, M. B. (2014) Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection. Antimicrobial Agents and Chemotherapy 58, 4885-4893.
[40] Ekins, S., Mottin, M., Ramos, P., Sousa, B. K. P., Neves, B. J., Foil, D. H., Zorn, K. M., Braga, R. C., Coffee, M., Southan, C., Puhl, A. C. and Andrade, C. H. (2020) Deja Vu: stimulating open drug discovery for SARS-CoV-2. Drug Discovery Today 25, 928-941.
[41] Ettman, C. K., Brown University School of Public Health, Providence, Rhode Island, Abdalla, S. M., Cohen, G. H., Columbia Mailman School of Public Health, New York, New York, Sampson, L., Vivier, P. M., Hassenfeld Child Health Innovation Institute, Providence, Rhode Island and Galea, S. (2020) Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Network Open 3, e2019686.
[42] Fagone, P., Ciurleo, R., Lombardo, S. D., Iacobello, C., Palermo, C. I., Shoenfeld, Y., Bendtzen, K., Bramanti, P. and Nicoletti, F. (2020) Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies. Autoimmunity Reviews 19, 102571.
[43] Fan, A. Y., Gu, S. and Alemi, S. F. (2020) Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis. Journal of Integrative Medicine 18, 385-394.
[44] Ferner, R. E. and Aronson, J. K. (2020) Chloroquine and hydroxychloroquine in covid-19. BMJ 1, m1432.
[45] Crisafulli, S., Isgrò, V., La Corte, L., Atzeni, F. and Trifirò, G. (2020) Potential role of anti-interleukin (IL)-6 drugs in the treatment of COVID-19: Rationale,clinical evidence and risks. Biodrugs 34, 415-422.
[46] Ferrario, C. M., Ahmad, S. and Groban, L. (2020) Mechanisms by which angiotensin-receptor blockers increase ACE2 levels. Nature Reviews Cardiology 17, 378-378.
[47] Fosbøl, E. L., Butt, J. H., Østergaard, L., Andersson, C., Selmer, C., Kragholm, K., Schou, M., Phelps, M., Gislason, G. H., Department of Cardiovascular Epidemiology and Research, The Danish Heart Foundation, Copenhagen, Denmark, Gerds, T. A., Torp-Pedersen, C. and Køber, L. (2020) Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA 324, 168.
[48] Gao, L., Xu, J. and Chen, S. (2020a) In Silico screening of potential chinese herbal medicine against COVID-19 by targeting SARS-CoV-2 3CLpro and angiotensin converting enzyme II using molecular docking. Chinese Journal of Integrative Medicine 26, 527-532.
[49] Gao, Y., Yan, L., Huang, Y., Liu, F., Zhao, Y., Cao, L., Wang, T., Sun, Q., Ming, Z., Zhang, L., Ge, J., Zheng, L., Zhang, Y., Wang, H., Zhu, Y., Zhu, C., Hu, T., Hua, T., Zhang, B., Yang, X., Li, J., Yang, H., Liu, Z., Xu, W., Guddat, L. W., Wang, Q., Lou, Z. and Rao, Z. (2020b) Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 368, 779-782.
[50] Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J., Turner, A. J., Raizada, M. K., Grant, M. B. and Oudit, G. Y. (2020) Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system. Circulation Research 126, 1456-1474.
[51] Ghisalberti, E. L. (2000) Lantana camara L. (Verbenaceae). Fitoterapia 71, 467-486.
[52] Gilbert, J., Henske, P., Singh, A. (2003) Rebuilding big pharma’s business model, in vivo. The Business & Medicine Report 21,73-80.
[53] Girija, P. L. T. and Sivan, N. (2020) Ayurvedic treatment of COVID-19/SARS-CoV-2: A case report. Journal of Ayurveda and Integrative Medicine (in press).
[54] Gorbalenya, A. E., Baker, S. C., Baric, R. S., Groot, de R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., Neuman, B. W., Penzar, D., Perlman, S., Poon, L. L. M., Samborskiy, D., Sidorov, I. A., Sola, I., Ziebuhr, J. (2020) Severe acute respiratory syndrome-related coronavirus: The species and its viruses - a statement of the coronavirus study group. (in press).
[55] Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F., X., Nicastri, E., Oda, R., Yo, K., Quiros-Roldan, E., Studemeister, A., Redinski, J., Ahmed, S., Bernett, J., Chelliah, D., Chen, D., Chihara, S., Cohen, S. H., Cunningham, J., D’Arminio Monforte, A., Ismail, S., Kato, H., Lapadula, G., L’Her, E., Maeno, T., Majumder, S., Massari, M., Mora-Rillo, M., Mutoh, Y., Nguyen, D., Verweij, E., Zoufaly, A., Osinusi, A. O., DeZure, A., Zhao, Y., Zhong, L., Chokkalingam, A., Elboudwarej, E., Telep, L., Timbs, L., Henne, I., Sellers, S., Cao, H., Tan, S. K., Winterbourne, L., Desai, P., Mera, R., Gaggar, A., Myers, R. P., Brainard, D. M., Childs, R. and Flanigan, T. (2020) Compassionate use of remdesivir for patients with severe Covid-19. New England Journal of Medicine 382, 2327-2336.
[56] Gross, L. Z. F., Sacerdoti, M., Piiper, A., Zeuzem, S., Leroux, A. E. and Biondi, R. M. (2020) ACE2, the Receptor that Enables Infection by SARS‐CoV‐2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators. Chemmedchem 15, 1682-1690.
[57] Gu, X.Y., Shen, X.F., Wang, L., Wu, Z.W., Li, F., Chen, B., Zhang, G.L. and Wang, M.K. (2018) Bioactive steroidal alkaloids from the fruits of Solanum nigrum. Phytochemistry 147, 125-131.
[58] Guerrero, L., Castillo, J., Quiñones, M., Garcia-Vallvé, S., Arola, L., Pujadas, G. and Muguerza, B. (2012) Inhibition of angiotensin-converting enzyme activity by flavonoids: structure-activity relationship studies. Plos One 7, e49493.
[59] Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., Bikdeli, B., Ahluwalia, N., Ausiello, J. C., Wan, E. Y., Freedberg, D. E., Kirtane, A. J., Parikh, S. A., Maurer, M. S., Nordvig, A. S., Accili, D., Bathon, J. M., Mohan, S., Bauer, K. A., Leon, M. B., Krumholz, H. M., Uriel, N., Mehra, M. R., Elkind, M. S. V., Stone, G. W., Schwartz, A., Ho, D. D., Bilezikian, J. P. and Landry, D. W. (2020) Extrapulmonary manifestations of COVID-19. Nature Medicine 26, 1017-1032.
[60] Gyebi, G. A., Ogunro, O. B., Adegunloye, A. P., Ogunyemi, O. M. and Afolabi, S. O. (2020) Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CLpro): an in silico screening of alkaloids and terpenoids from African medicinal plants. Journal of Biomolecular Structure and Dynamics 12, 1-13.
[61] Haggag, Y. A., El-Ashmawy, N. E. and Okasha, K. M. (2020) Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection? Medical Hypotheses 144, 109957.
[62] Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G. and van Goor, H. (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology 203, 631-637.
[63] Heredia, A., Le, N., Gartenhaus, R. B., Sausville, E., Medina-Moreno, S., Zapata, J. C., Davis, C., Gallo, R. C. and Redfield, R. R. (2015) Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice. Proceedings of the National Academy of Sciences 112, 9412-9417.
[64] Herbert, J. M., Maffrand, J. P., Taoubi, K., Augereau, J. M., Fouraste, I. and Gleye, J. (1991) Verbascoside isolated from Lantana camara, an inhibitor of protein kinase C. Journal of Natural Products 54, 1595-1600.
[65] Hilgenfeld, R. and Peiris, M. (2013) From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antiviral Research 100, 286-295.
[66] Ho, T., Wu, S., Chen, J., Li, C. and Hsiang, C. (2007) Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Research 74, 92-101.
[67] Hoffmann, M., Schroeder, S., Kleine-Weber, H., Müller, M. A., Drosten, C. and Pöhlmann, S. (2020) Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrobial Agents and Chemotherapy 64
[68] Horby, P., Lim, W. S., Emberson, J. R., Mafham, M., Bell, J. L., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., Prudon, B., Green, C., Felton, T., Chadwick, D., Rege, K., Fegan, C., Chappell, L. C., Faust, S. N., Jaki, T., Jeffery, K., Montgomery, A., Rowan, K., Juszczak, E., Baillie, J. K., Haynes, R. and Landray, M. J. (2020) Dexamethasone in hospitalized patients with COVID-19 - preliminary report. New England Journal of Medicine (in press).
[69] Horie, S., McNicholas, B., Rezoagli, E., Pham, T., Curley, G., McAuley, D., O’Kane, C., Nichol, A., dos Santos, C., Rocco, P. R. M., Bellani, G. and Laffey, J. G. (2020) Emerging pharmacological therapies for ARDS: COVID-19 and beyond. Intensive Care Medicine 2, 1-19.
[70] Huang, H., Syu, K. and Lin, J. (2010) Chemical composition of Solanum nigrum Linn extract and induction of autophagy by leaf water extract and its major flavonoids in AU565 breast cancer cells. Journal of Agricultural and Food Chemistry 58, 8699-8708.
[71] Huang, F., Li, Y., Leung, E. L., Liu, X., Liu, K., Wang, Q., Lan, Y., Li, X., Yu, H., Cui, L., Luo, H. and Luo, L. (2020) A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). Pharmacological Research 158, 104929.
[72] Ibrahim, M. A. A., Abdeljawaad, K. A. A., Abdelrahman, A. H. M. and Hegazy, M. F. (2020a) Natural-like products as potential SARS-CoV-2 M(pro) inhibitors: In-silico drug discovery. Journal of Biomolecular Structure and Dynamics 91, 1-13.
[73] Ibrahim, H., Perl, A., Smith, D., Lewis, T., Kon, Z., Goldenberg, R., Yarta, K., Staniloae, C. and Williams, M. (2020b) Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clinical Immunology 219, 108544.
[74] Inal, J. (2020) Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy. Clinical Science 134, 1301-1304.
[75] Jacobs, M., Rodger, A., Bell, D. J., Bhagani, S., Cropley, I., Filipe, A., Gifford, R. J., Hopkins, S., Hughes, J., Jabeen, F., Johannessen, I., Karageorgopoulos, D., Lackenby, A., Lester, R., Liu, R. S., MacConnachie, A., Mahungu, T., Martin, D., Marshall, N., Mepham, S., Orton, R., Palmarini, M., Patel, M., Perry, C., Peters, S. E., Porter, D., Ritchie, D., Ritchie, N. D., Seaton, R. A., Sreenu, V. B., Templeton, K., Warren, S., Wilkie, G. S., Zambon, M., Gopal, R. and Thomson, E. C. (2016) Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 388, 498-503.
[76] Jamaluddin, M., Meng, T., Sun, J., Boldogh, I., Han, Y. and Brasier, A. R. (2000) Angiotensin II induces nuclear factor (NF)-kappab1 isoforms to bind the angiotensinogen gene acute-phase response element: a stimulus-specific pathway for NF-kappab activation. Molecular Endocrinology (Baltimore, Md.) 14, 99-113.
[77] Java, A., Apicelli, A. J., Liszewski, M. K., Coler-Reilly, A., Atkinson, J. P., Kim, A. H. J. and Kulkarni, H. S. (2020) The complement system in COVID-19: friend and foe? JCI Insight 5, e140711.
[78] Jose, R. J. and Manuel, A. (2020) COVID-19 cytokine storm: the interplay between inflammation and coagulation. the Lancet Respiratory Medicine 8, e46-e47.
[79] Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., Duan, Y., Yu, J., Wang, L., Yang, K., Liu, F., Jiang, R., Yang, X., You, T., Liu, X., Yang, X., Bai, F., Liu, H., Liu, X., Guddat, L. W., Xu, W., Xiao, G., Qin, C., Shi, Z., Jiang, H., Rao, Z. and Yang, H. (2020) Structure of M(Pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289-293.
[80] Joshi, T., Joshi, T., Sharma, P., Mathpal, S., Pundir, H., Bhatt, V. and Chandra, S. (2020) In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking. European Review for Medical and Pharmacological Sciences 24, 4529-4536.
[81] Kandimalla, R., John, A., Abburi, C., Vallamkondu, J. and Reddy, P. H. (2020) Current status of multiple drug molecules, and vaccines: An update in SARS-CoV-2 therapeutics. Molecular Neurobiology 57, 4106-4116.
[82] Kang, Y., Chen, T., Mui, D., Ferrari, V., Jagasia, D., Scherrer-Crosbie, M., Chen, Y. and Han, Y. (2020) Cardiovascular manifestations and treatment considerations in COVID-19. Heart 106, 1132-1141.
[83] Kalra, R. S., Tomar, D., Meena, A. S. and Kandimalla, R. (2020) SARS-CoV-2, ACE2, and hydroxychloroquine: cardiovascular complications, therapeutics, and clinical readouts in the current settings. Pathogens 9, 546.
[84] Kiran, G., Karthik, L., Shree Devi, M. S., Sathiyarajeswaran, P., Kanakavalli, K., Kumar, K. M. and Ramesh Kumar, D. (2020) In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein. Journal of Ayurveda and Integrative Medicine (in press).
[85] Kumar, Y., Singh, H. and Patel, C. N. (2020) In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Journal of Infection and Public Health 13, 1210-1223.
[86] Kuba, K., Imai, Y. and Penninger, J. M. (2013) Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. Circulation Journal 77, 301-308.
[87] Kuno, T., Takahashi, M., Obata, R. and Maeda, T. (2020) Cardiovascular comorbidities, cardiac injury, and prognosis of COVID-19 in New York city. American Heart Journal 226, 24-25.
[88] Lee, B., Lee, J. A., Kim, K., Choi, J. and Jung, H. (2020) A consensus guideline of herbal medicine for coronavirus disease 2019. Integrative Medicine Research 9, 100470.
[89] Li, W., Zhang, C., Sui, J., Kuhn, J. H., Moore, M. J., Luo, S., Wong, S., Huang, I., Xu, K., Vasilieva, N., Murakami, A., He, Y., Marasco, W. A., Guan, Y., Choe, H. and Farzan, M. (2005) Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. The EMBO Journal 24, 1634-1643.
[90] Li, M., Li, L., Zhang, Y. and Wang, X. (2020a) Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infectious Diseases of Poverty 9, 45.
[91] Li, B., Yang, J., Zhao, F., Zhi, L., Wang, X., Liu, L., Bi, Z. and Zhao, Y. (2020b) Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology 109, 531-538.
[92] Liu, W., and Li, H. (2020) COVID-19: Attacks the 1-Beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv (in press).
[93] Lo, M. K., Jordan, R., Arvey, A., Sudhamsu, J., Shrivastava-Ranjan, P., Hotard, A. L., Flint, M., McMullan, L. K., Siegel, D., Clarke, M. O., Mackman, R. L., Hui, H. C., Perron, M., Ray, A. S., Cihlar, T., Nichol, S. T. and Spiropoulou, C. F. (2017) GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Scientific Reports 7, 43395.
[94] Lopes, R. D., Macedo, A. V. S., de Barros E. S. P. G. M., Moll-Bernardes, R. J., Feldman, A., D’Andréa Saba Arruda, G., de Souza, A. S., de Albuquerque, D. C., Mazza, L., Santos, M. F., Salvador, N. Z., Gibson, C. M., Granger, C. B., Alexander, J. H. and de Souza, O. F. (2020) Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–the brace corona trial. American Heart Journal 226, 49-59.
[95] Mackey, K., King, V. J., Gurley, S., Kiefer, M., Liederbauer, E., Vela, K., Sonnen, P. and Kansagara, D. (2020) Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: A living systematic review. Annals of Internal Medicine 173, 195-203.
[96] Mahase, E. (2020) Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds. BMJ 369, m2422.
[97] Mahmudpour, M., Roozbeh, J., Keshavarz, M., Farrokhi, S. and Nabipour, I. (2020) COVID-19 cytokine storm: The anger of inflammation. Cytokine 133, 155151.
[98] Mak, E. (2020) Chinese biotech’s apply new tech to accelerate drug R&D for COVID-19. Available at: (Accessed: February 25, 2020)
[99] Mani, J. S., Johnson, J. B., Steel, J. C., Broszczak, D. A., Neilsen, P. M., Walsh, K. B. and Naiker, M. (2020) Natural product-derived phytochemicals as potential agents against coronaviruses: A review. Virus Research 284, 197989.
[100] Maurya, V. K., Kumar, S., Prasad, A. K., Bhatt, M. L. B. and Saxena, S. K. (2020) Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor. Virusdisease 31, 179-193.
[101] McCullough, P. A., Kelly, R. J., Ruocco, G., Lerma, E., Tumlin, J., Wheelan, K. R., Katz, N., Lepor, N. E., Vijay, K., Carter, H., Singh, B., McCullough, S. P., Bhambi, B. K., Palazzuoli, A., De Ferrari, G. M., Milligan, G. P., Safder, T., Tecson, K. M., Wang, D. D., McKinnon, J. E., O’Neill, W. W., Zervos, M. and Risch, H. A. (2020) Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. The American Journal of Medicine (in press).
[102] Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S. and Manson, J. J. (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 395, 1033-1034.
[103] Mehta, P. K. and Griendling, K. K. (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. American Journal of Physiology-Cell Physiology 292, C82-C97.
[104] Mevada, V., Dudhagara, P., Gandhi, H., Vaghamshi, N., Beladiya, U., Patel, R. (2020) Drug repurposing of approved drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for combating COVID19. ChemRxiv. (in press).
[105] Messerli, F. H., Siontis, G. C. M. and Rexhaj, E. (2020) COVID-19 and renin angiotensin blockers. Circulation 141, 2042-2044.
[106] Mohammed El Tabaa, Manar. and Mohammed El Tabaa, Maram (2020) Targeting Neprilysin (Nep) Pathways: A Potential New Hope to Defeat Covid-19 Ghost. Biochem Pharmacol 178, 114057.
[107] Nahrstedt, A., Kant, J. and Wray, V. (1982) Acalyphin, a cyanogenic glucoside from Acalypha indica. Phytochemistry 21, 101-105.
[108] Narkhede, R. R., Pise, A. V., Cheke, R. S. and Shinde, S. D. (2020) Recognition of natural products as potential inhibitors of COVID-19 main protease (Mpro): In-Silico evidences. Natural Products and Bioprospecting (in press).
[109] Nicoletti, F., Fagone, P., Meroni, P., McCubrey, J. and Bendtzen, K. (2011) Mtor as a multifunctional therapeutic target in HIV infection. Drug Discovery Today 16, 715-721.
[110] Nathan, C. (2020) Neutrophils and COVID-19:nots, nets, and knots. Journal of Experimental Medicine 217, e20201439.
[111] Nguyen, T. T. H., Woo, H., Kang, H., Nguyen, V. D., Kim, Y., Kim, D., Ahn, S., Xia, Y. and Kim, D. (2012) Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris. Biotechnology Letters 34, 831-838.
[112] Oostra, M., de Haan, C. A. M. and Rottier, P. J. M. (2007) The 29-nucleotide deletion present in human but not in animal severe acute respiratory syndrome coronaviruses disrupts the functional expression of open reading frame 8. Journal of Virology 81, 13876-13888.
[113] Pai, W., Lo, W., Hsu, T., Peng, C. and Wang, H. (2017) Angiotensin-(1-7) inhibits thrombin-induced endothelial phenotypic changes and reactive oxygen species production via NADPH oxidase 5 downregulation. Frontiers in Physiology 8, 994.
[114] Paintsil, E. and Cheng, Y. (2009) Antiviral agents. Encyclopedia of Microbiology 223-257.
[115] Pal, A., Pawar, A., Goswami, K., Sharma, P. and Prasad, R. (2020) Hydroxychloroquine and Covid-19: A cellular and molecular biology based update. Indian Journal of Clinical Biochemistry 35, 274-284.
[116] Patel, V. B., Zhong, J., Grant, M. B. and Oudit, G. Y. (2016) Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circulation Research 118, 1313-1326.
[117] Patil, T. R. and Limaye, R. P. (2017) Effect of Euphorbia prostrata on the wound healing in excisional wound model in rats. International Journal of Pharmacognosy and Phytochemical Research 9, 10.25258/phyto.v9i09.10310.
[118] Patwardhan, B., Gautam, P. C., Gautam, M., Tillu, G., Chopra, A., Gairola, S. and Jadhav, S. (2020) Ayurveda Rasayana in prophylaxis of COVID-19. Current Science 118,1158-1160.
[119] Petralia, M. C., Mazzon, E., Fagone, P., Basile, M. S., Lenzo, V., Quattropani, M. C., Di Nuovo, S., Bendtzen, K. and Nicoletti, F. (2020) The cytokine network in the pathogenesis of major depressive disorder. Close to translation?. Autoimmunity Reviews 19, 102504.
[120] Pirola, C. J. and Sookoian, S. (2020) Estimation of renin-angiotensin-aldosterone-system (RAAS)-inhibitor effect on the COVID-19 outcome: A meta-analysis. Journal of Infection 81, 276-281.
[121] Pizzorno, A., Padey, B., Dubois, J., Julien, T., Traversier, A., Dulière, V., Brun, P., Lina, B., Rosa-Calatrava, M. and Terrier, O. (2020) In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Research 181, 104878.
[122] Rahman, N., Basharat, Z., Yousuf, M., Castaldo, G., Rastrelli, L. and Khan, H. (2020) Virtual screening of natural products against type II transmembrane serine protease (TMPRSS2), the priming agent of coronavirus 2 (SARS-CoV-2). Molecules 25, 2271.
[123] Ramaiah, M. J. (2020) Mtor inhibition and P53 Activation, Micrornas: The possible therapy against pandemic COVID-19. Gene Reports 20, 100765.
[124] Rane, J.S., Chatterjee, A., Kumar, K. and Ray, S. (2020) Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: An in silico study for drug development. Chemrxiv (in press)
[125] Reichert, J. M. (2003) Trends in development and approval times for new therapeutics in the United States. Nature Reviews Drug Discovery 2, 695-702.
[126] Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E. and Stebbing, J. (2020a) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet 395, e30-e31.
[127] Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell, C.-R. C., Barnaby, D. P., Becker, L. B., Chelico, J. D., Cohen, S. L., Cookingham, J., Coppa, K., Diefenbach, M. A., Dominello, A. J., Duer-Hefele, J., Falzon, L., Gitlin, J., Hajizadeh, N., Harvin, T. G., Hirschwerk, D. A., Kim, E. J., Kozel, Z. M., Marrast, L. M., Mogavero, J. N., Osorio, G. A., Qiu, M. and Zanos, T. P. (2020b) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 323, 2052.
[128] Roche, J. A. and Roche, R. (2020) A hypothesized role for dysregulated bradykinin signaling in COVID‐19 respiratory complications. The FASEB Journal 34, 7265-7269.
[129] Romagnoli, S., Peris, A., De Gaudio, A. R. and Geppetti, P. (2020) SARS-CoV-2 and COVID-19: From the bench to the bedside. Physiological Reviews 100, 1455-1466.
[130] Rosendaal, F. R. (2020) Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010International Journal of Antimicrobial Agents 56, 106063.
[131] Rowley, A. H. (2020) Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nature Reviews Immunology 20, 453-454.
[132] Ruiz-Ortega, M., Lorenzo, O., Suzuki, Y., Rupérez, M. and Egido, J. (2001) Proinflammatory actions of angiotensins. Current Opinion in Nephrology and Hypertension 10, 321-329.
[133] Rushworth, C. A., Guy, J. L. and Turner, A. J. (2008) Residues affecting the chloride regulation and substrate selectivity of the angiotensin-converting enzymes (ACE and ACE2) identified by site-directed mutagenesis. FEBS Journal 275, 6033-6042.
[134] Ryu, Y. B., Jeong, H. J., Kim, J. H., Kim, Y. M., Park, J., Kim, D., Naguyen, T. T. H., Park, S., Chang, J. S. and Park, K. H. (2010) Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition. Bioorganic & Medicinal Chemistry 18, 7940-7947.
[135] Sallenave, J. and Guillot, L. (2020) Innate immune signaling and proteolytic pathways in the resolution or exacerbation of SARS-CoV-2 in Covid-19: key therapeutic targets? Frontiers in Immunology 11
[136] Samuel, C. E. (2001) Antiviral actions of interferons. Clinical Microbiology Reviews 14, 778-809.
[137] Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. and Cutrell, J. B. (2020) Pharmacologic Treatments for coronavirus disease 2019 (COVID-19). JAMA 328, 1824-1836.
[138] Sano, M., Fukuda, K., Kodama, H., Pan, J., Saito, M., Matsuzaki, J., Takahashi, T., Makino, S., Kato, T. and Ogawa, S. (2000) Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. Journal of Biological Chemistry 275, 29717-29723.
[139] Santos, R. A. S., Sampaio, W. O., Alzamora, A. C., Motta-Santos, D., Alenina, N., Bader, M. and Campagnole-Santos, M. J. (2018) The ACE2/Angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7). Physiological Reviews 98, 505-553.
[140] Santos, J., Brierley, S., Gandhi, M. J., Cohen, M. A., Moschella, P. C. and Declan, A. B. L. (2020) Repurposing therapeutics for potential treatment of SARS-CoV-2: A review. Viruses 12, 705.
[141] Schrader, T., Dudek, S. E., Schreiber, A., Ehrhardt, C., Planz, O. and Ludwig, S. (2018) The clinically approved MEK inhibitor Trametinib efficiently blocks influenza a virus propagation and cytokine expression. Antiviral Research 157, 80-92.
[142] Schwarz, S., Sauter, D., Wang, K., Zhang, R., Sun, B., Karioti, A., Bilia, A., Efferth, T. and Schwarz, W. (2014) Kaempferol Derivatives as Antiviral Drugs against the 3a Channel Protein of Coronavirus. Planta Medica 80, 177-182.
[143] Siddiqi, H. K. and Mehra, M. R. (2020) COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. The Journal of Heart and Lung Transplantation 39, 405-407.
[144] Silhol, F., Sarlon, G., Deharo, J. and Vaïsse, B. (2020) Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system? Hypertension Research 43, 854-856.
[145] da Silva, J. K. R., Figueiredo, P. L. B., Byler, K. G. and Setzer, W. N. (2020) Essential oils as antiviral agents, potential of essential oils to treat SARS-CoV-2 infection: An in-silic o investigation. International Journal of Molecular Sciences 21, 3426.
[146] Skurk, T., van Harmelen, V. and Hauner, H. (2004) Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB. Arteriosclerosis, Thrombosis, and Vascular Biology 24, 1199-1203.
[147] Song, H. D., Tu, C. C., Zhang, G. W., Wang, S. Y., Zheng, K., Lei, L. C., Chen, Q. X., Gao, Y. W., Zhou, H. Q., Xiang, H., Zheng, H. J., Chern, S. W., Cheng, F., Pan, C. M., Xuan, H., Chen, S. J., Luo, H. M., Zhou, D. H., Liu, Y. F., He, J. F., Qin, P. Z., Li, L. H., Ren, Y. Q., Liang, W. J., Yu, Y. D., Anderson, L., Wang, M., Xu, R. H., Wu, X. W., Zheng, H. Y., Chen, J. D., Liang, G., Gao, Y., Liao, M., Fang, L., Jiang, L. Y., Li, H., Chen, F., Di, B., He, L. J., Lin, J. Y., Tong, S., Kong, X., Du, L., Hao, P., Tang, H., Bernini, A., Yu, X. J., Spiga, O., Guo, Z. M., Pan, H. Y., He, W. Z., Manuguerra, J. C., Fontanet, A., Danchin, A., Niccolai, N., Li, Y. X., Wu, C. I. and Zhao, G. P. (2005) Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proceedings of the National Academy of Sciences 102, 2430-2435.
[148] Soy, M., Keser, G., Atagündüz, P., Tabak, F., Atagündüz, I. and Kayhan, S. (2020) Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clinical Rheumatology 39, 2085-2094.
[149] Stebbing, J., Krishnan, V., de Bono, S., Ottaviani, S., Casalini, G., Richardson, P. J., Monteil, V., Lauschke, V. M., Mirazimi, A., Youhanna, S., Tan, Y. J., Baldanti, F., Sarasini, A., Terres, J. A. R., Nickoloff, B. J., Higgs, R. E., Rocha, G., Byers, N. L., Schlichting, D. E., Nirula, A., Cardoso, A., Corbellino, M. and Sacco Baricitinib Study, G. (2020) Mechanism of Baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Molecular Medicine 12, e12697.
[150] Tai, B. H., Nhiem, N. X., Van Doan, V., Yen, P. H., Quang, T. H., Trang, D. T., Yen, D. T. H., Cuc, N. T. and Van Kiem, P. (2018) Isolation of spirostanol glycosides from Solanum nigrum. Vietnam Journal of Chemistry 56, 548-552.
[151] Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A. and Ng, L. F. P. (2020) The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology 20, 363-374.
[152] Tan, E. L. C., Ooi, E. E., Lin, C., Tan, H. C., Ling, A. E., Lim, B. and Stanton, L. W. (2004) Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerging Infectious Diseases 10, 581-586.
[153] Tang, N., Li, D., Wang, X. and Sun, Z. (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis 18, 844-847.
[154] Tchesnokov, E., Feng, J., Porter, D. and Götte, M. (2019) Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 11, 326.
[155] Troiani, T., Vecchione, L., Martinelli, E., Capasso, A., Costantino, S., Ciuffreda, L. P., Morgillo, F., Vitagliano, D., D’Aiuto, E., De Palma, R., Tejpar, S., Van Cutsem, E., De Lorenzi, M., Caraglia, M., Berrino, L. and Ciardiello, F. (2012) Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. British Journal of Cancer 106, 1648-1659.
[156] Uhal, B. D., Li, X., Xue, A., Gao, X. and Abdul-Hafez, A. (2011) Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1-7/Mas axis. American Journal of Physiology-Lung Cellular and Molecular Physiology 301, L269-L274.
[157] Ul Qamar, M. T., Alqahtani, S. M., Alamri, M. A. and Chen, L. L. (2020) Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants. Journal of Pharmaceutical Analysis 10, 313–319.
[158] Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., Pia, L., Risson, E., Saffern, M., Salome, B., Esai Selvan, M., Spindler, M. P., Tan, J., van der Heide, V., Gregory, J. K., Alexandropoulos, K., Bhardwaj, N., Brown, B. D., Greenbaum, B., Gumus, Z. H., Homann, D., Horowitz, A., Kamphorst, A. O., Curotto de Lafaille, M. A., Mehandru, S., Merad, M., Samstein, R. M. and Sinai Immunology Review Project (2020) Immunology of COVID-19: Current state of the science. Immunity 52, 910-941.
[159] Van Laecke, S. and Van Biesen, W. (2017) Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect? Kidney International 91, 1271-1274.
[160] Viana, S. D., Nunes, S. and Reis, F. (2020) ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis. Ageing Research Reviews 62, 101123.
[161] Verdecchia, P., Cavallini, C., Spanevello, A. and Angeli, F. (2020) COVID-19: ACE2centric infective disease? Hypertension 76, 294-299.
[162] Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., Wang, Y., Ding, D., Wu, F., Tang, X., Ye, X., Ye, Y., Liu, B., Yang, J., Yin, W., Wang, A., Fan, G., Zhou, F., Liu, Z., Gu, X., Xu, J., Shang, L., Zhang, Y., Cao, L., Guo, T., Wan, Y., Qin, H., Jiang, Y., Jaki, T., Hayden, F. G., Horby, P. W., Cao, B. and Wang, C. (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet 395, 1569-1578.
[163] Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., Prescott, H. C. (2020) Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). JAMA 324, 782.
[164] World Health Organization. (2020) Coronavirus disease (COVID-19) pandemic. Availableat: (Accessed: September 27, 2020).
[165] Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X., Zheng, M., Chen, L. and Li, H. (2020) Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B 10, 766-788.
[166] Yang, J. K., Feng, Y., Yuan, M. Y., Yuan, S. Y., Fu, H. J., Wu, B. Y., Sun, G. Z., Yang, G. R., Zhang, X. L., Wang, L., Xu, X., Xu, X. P. and Chan, J. C. N. (2006) Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic Medicine 23, 623-628.
[167] Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., Zhan, S., Lu, R., Li, H., Tan, W. and Liu, D. (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases 71, 732-739.
[168] Ye, Q., Wang, B. and Mao, J. (2020) The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. Journal of Infection 80, 607-613.
[169] Y. Yuen, C. K., Lam, J. Y., Wong, W. M., Mak, L. F., Wang, X., Chu, H., Cai, J. P., Jin, D. Y., To, K. K., Chan, J. F., Yuen, K. Y. and Kok, K. H. (2020) SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerging Microbes and Infections 9, 1418-1428.
[170] Zhang, X. W. and Yap, Y. L. (2004) Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorganic and Medicinal Chemistry 12, 2517-2521.
[171] Zhang, Y., Zheng, N., Hao, P., Cao, Y. and Zhong, Y. (2005) A molecular docking model of SARS-CoV S1 protein in complex with its receptor, human ACE2. Computational Biology and Chemistry 29, 254-257.
[172] Zhang, L. and Zhou, R. (2020) Structural basis of the potential binding mechanism of remdesivir to SARS-CoV-2 RNA-dependent RNA polymerase. Journal of Physical Chemistry B 124, 6955-6962.
[173] Zhang, X., Zhang, Y., Qiao, W., Zhang, J. and Qi, Z. (2020) Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. International Immunopharmacology 86, 106749.
[174] Zheng, Y., Li, R. and Liu, S. (2020) Immunoregulation with mTOR inhibitors to prevent covid-19 severity: a novel intervention strategy beyond vaccines and specific antiviral medicines. Journal of Medical Virology 92, 1495-1500.
[175] Zhang, Y., Zhang, J., Chen, Y., Luo, B., Yuan, Y., Huang, F., Yang, T., Yu, F., Liu, J., Liu, B., Song, Z., Chen, J., Pan, T., Xu Zhang, X., Li, Y., Li, R., Huang. W., Xiao, F., and Zhang, H. (2020) The ORF8 Protein of SARS-CoV-2 mediates immune evasion through potently downregulating MHC-I bioRxiv (in press).
[176] Zhong, N., Zheng, B., Li, Y., Poon, L., Xie, Z., Chan, K., Li, P., Tan, S., Chang, Q., Xie, J., Liu, X., Xu, J., Li, D., Yuen, K., Peiris, J. and Guan, Y. (2003) Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. The Lancet 362, 1353-1358.
[177] Zhou, X., He, X., Wang, G., Gao, H., Zhou, G., Ye, W. and Yao, X. (2006) Steroidal saponins from Solanum nigrum. Journal of Natural Products 69, 1158-1163.
[178] Zou, Y., Guo, H., Zhang, Y., Zhang, Z., Liu, Y., Wang, J., Lu, H. and Qian, Z. (2020) Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China. Bioscience Trends 14, 285-289.
[1] Niloofar Deravi, Mobina Fathi, Kimia Vakili, Shirin Yaghoobpoor, Marzieh Pirzadeh, Melika Mokhtari, Tara Fazel, Elahe Ahsan, Samad Ghaffari. SARS-CoV-2 infection in patients with diabetes mellitus and hypertension: a systematic review[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 385-397.
[2] Jun Zhang, Kristen M. Tecson, Peter A. McCullough. Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 315-319.
[3] Jun Zhang, Peter A. McCullough, Kristen M. Tecson. Vitamin D deficiency in association with endothelial dysfunction: Implications for patients with COVID-19[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 339-344.
[4] Allison Zimmerman, Dinesh Kalra. Usefulness of machine learning in COVID-19 for the detection and prognosis of cardiovascular complications[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 345-352.
[5] Ajay K. Mahenthiran, Ashorne K. Mahenthiran, Jo Mahenthiran. Cardiovascular system and COVID-19: manifestations and therapeutics[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 399-409.
[6] Kimia Vakili, Mobina Fathi, Aiyoub Pezeshgi, Ashraf Mohamadkhani, Mohammadreza Hajiesmaeili, Mostafa Rezaei-Tavirani, Fatemeh Sayehmiri. Critical complications of COVID-19: A descriptive meta-analysis study[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 433-442.
[7] Matteo Cameli, Maria Concetta Pastore, Michael Henein, Hatem Soliman Aboumarie, Giulia Elena Mandoli, Flavio D'Ascenzi, Paolo Cameli, Federico Franchi, Sergio Mondillo, Serafina Valente. Safe performance of echocardiography during the COVID-19 pandemic: a practical guide[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 217-223.
[8] Gayatri Setia, Jeffrey Tyler, Alan Kwan, Josh Faguet, Shilpa Sharma, Siddharth Singh, Babak Azarbal, Rose Tompkins, Dinora Chinchilla, Sara Ghandehari. High thrombus burden despite thrombolytic therapy in ST-elevation myocardial infarction in a patient with COVID-19[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 289-295.
[9] Peter A. McCullough, John Eidt, Janani Rangaswami, Edgar Lerma, James Tumlin, Kevin Wheelan, Nevin Katz, Norman E. Lepor, Kris Vijay, Sandeep Soman, Bhupinder Singh, Sean P. McCullough, Haley B. McCullough, Alberto Palazzuoli, Gaetano M. Ruocco, Claudio Ronco. Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infection[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 1-7.
No Suggested Reading articles found!